Related references
Note: Only part of the references are listed.A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma
Sikander Ailawadhi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma
Tycel Phillips et al.
INVESTIGATIONAL NEW DRUGS (2019)
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients
Francesco Gaudio et al.
ANNALS OF HEMATOLOGY (2019)
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
CANCER (2019)
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Sundar Jagannath et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
Hao Xie et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Elias J. Jabbour et al.
CANCER (2019)
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Meghdad Abdollahpour-Alitappeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia
Joseph Wynne et al.
BLOOD ADVANCES (2019)
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Amandeep Aujla et al.
BIOMARKER RESEARCH (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Thomas Nittoli et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce et al.
BLOOD (2018)
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up
Robert J. Kreitman et al.
BLOOD (2018)
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
Partow Kebriaei et al.
BONE MARROW TRANSPLANTATION (2018)
Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CANCER (2018)
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Marek Trneny et al.
HAEMATOLOGICA (2018)
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
Anastasios Stathis et al.
INVESTIGATIONAL NEW DRUGS (2018)
Advances in CD30-and PD-1-targeted therapies for classical Hodgkin lymphoma
Yucai Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Current trials for frontline therapy of mantle cell lymphoma
Raphael E. Steiner et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Precision therapy for acute myeloid leukemia
Xue Yang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation
Robert W. Chen et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2018)
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial
Owen A. O'Connor et al.
LANCET ONCOLOGY (2018)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J. Kreitman et al.
LEUKEMIA (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Marek Trneny et al.
HAEMATOLOGICA (2018)
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial
Elias Jabbour et al.
JAMA ONCOLOGY (2018)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz et al.
BLOOD (2018)
Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Ilana R. Yurkiewicz et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage
Elias Jabbour et al.
CANCER (2018)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Alex F. Herrera et al.
BLOOD (2018)
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Nam H. Dang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ranjana H. Advani et al.
CLINICAL CANCER RESEARCH (2017)
How precise is precision medicine in hematology?
Carlo Gambacorti-Passerini et al.
HAEMATOLOGICA (2017)
Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix
Remy Gebleux et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia
Sakiko Yoshida et al.
LEUKEMIA & LYMPHOMA (2017)
How precise is precision medicine in hematology?
Carlo Gambacorti-Passerini et al.
HAEMATOLOGICA (2017)
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
Swapna Thota et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future
Heather E. Vezina et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Emerging therapies for acute myeloid leukemia
Caner Saygin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma
Narendranath Epperla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
The role of B cell antigen receptors in mantle cell lymphoma
Michael Fichtner et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
Kurt Schoenfeld et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Dennis A. Eichenauer et al.
LANCET ONCOLOGY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
Hagop M. Kantarjian et al.
LANCET HAEMATOLOGY (2017)
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
Stuart W. Hicks et al.
NEOPLASIA (2017)
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma
Randeep Sangha et al.
JOURNAL OF DRUG ASSESSMENT (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Shengnan Yu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
A critical epithelial survival axis regulated by MCL-1 maintains thymic function in mice
Reema Jain et al.
BLOOD (2017)
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Naegele et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study
Daniel J. DeAngelo et al.
BLOOD ADVANCES (2017)
The development of bispecific antibodies and their applications in tumor immune escape
Xiaolong Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial
Pier Luigi Zinzani et al.
BLOOD (2017)
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70
Taofeek Kunle Owonikoko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
Lydia Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy
Andre Goy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
Bertrand Coiffier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer
Hongwen Li et al.
CANCER BIOLOGY & THERAPY (2016)
The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F
Mira Woitok et al.
CANCER LETTERS (2016)
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
Anette Sommer et al.
CANCER RESEARCH (2016)
Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+B-cell Non-Hodgkin Lymphoma
Michinori Ogura et al.
CLINICAL CANCER RESEARCH (2016)
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Linkers Having a Crucial Role in Antibody-Drug Conjugates
Jun Lu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
A Novel Affibody-Auristatin E Conjugate With a Potent and Selective Activity Against HER2+ Cell Lines
Alicja M. Sochaj-Gregorczyk et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth
David Cunningham et al.
PROSTATE (2016)
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
Tilman Schlothauer et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2016)
Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
Andrew B. Waight et al.
PLOS ONE (2016)
Conformational Difference in Human IgG2 Disulfide Isoforms Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry
Aming Zhang et al.
BIOCHEMISTRY (2015)
Antibody-drug conjugates as novel anti-cancer chemotherapeutics
Christina Peters et al.
BIOSCIENCE REPORTS (2015)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
Characterization of Cysteine-Linked Conjugation Profiles of Immunoglobulin G1 and Immunoglobulin G2 Antibody-Drug Conjugates
Brian Wiggins et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A. Palanca-Wessels et al.
LANCET ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M. Pfeifer et al.
LEUKEMIA (2015)
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma
Nina D. Wagner-Johnston et al.
LEUKEMIA & LYMPHOMA (2015)
AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML
Daniel S. Pereira et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Boris Shor et al.
MOLECULAR IMMUNOLOGY (2015)
Design of Coltuximab Ravtansine, a CD19-Targeting Antibody Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation
E. Erica Hong et al.
MOLECULAR PHARMACEUTICS (2015)
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Jia Ruan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K. Gopal et al.
BLOOD (2015)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Production of Site-Specific Antibody-Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
Erik S. Zimmerman et al.
BIOCONJUGATE CHEMISTRY (2014)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
Nizar M. Tannir et al.
INVESTIGATIONAL NEW DRUGS (2014)
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
Jutta Deckert et al.
BLOOD (2013)
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
Jonathan L. Kaufman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
Hagop Kantarjian et al.
CANCER (2013)
Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
Luis Fayad et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma
Dongwei Li et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Milatuzumab-SN-38 Conjugates for the Treatment of CD74 Cancers
Serengulam V. Govindan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Eric Sanchez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals
Rosa Lapalombella et al.
CANCER CELL (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia
Pier Paolo Piccaluga et al.
LEUKEMIA & LYMPHOMA (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology
Saileta Prabhu et al.
THERAPEUTIC DELIVERY (2011)
Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
Simone Jeger et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
Ralph F. Alderson et al.
CLINICAL CANCER RESEARCH (2009)
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy
Kenji Ishitsuka et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Xiaobin Zhao et al.
BLOOD (2007)
CD74: A new candidate target for the immunotherapy of B-Cell neoplasms
Rhona Stein et al.
CLINICAL CANCER RESEARCH (2007)
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
MSK Sutherland et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
YV Kovtun et al.
CANCER RESEARCH (2006)
CD27 and CD70 in T cell and B cell activation
J Borst et al.
CURRENT OPINION IN IMMUNOLOGY (2005)
The role of interleukin-2 receptor alpha in cancer
DJ Kuhn et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
AC Lazar et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2005)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities
G Saito et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Share Paper
